Événements
EASL – The Digital International Liver Congress 2020
27-29 août 2020
Congrès virtuel
ENYO Pharma était présente du 27 au 29 août 2020 au congrès virtuel international sur le foie (EASL) et a présenté 2 posters :
“Characterization of EYP001 a novel, potent and selective FXR agonist in in vitro 3D human liver models”
“A novel small molecule modulating the mitochondrial NEET (CISD) proteins activity improves inflammation and fibrosis in a diet-induced model of non-alcoholic steatohepatitis”
J.P. Morgan 2020 – 38th Annual Healthcare Conference
13 – 16 January, 2020
San Francisco, USA
“ENYO Pharma team was present at San Francisco during the J.P. Morgan conference, which is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.”
ENYO Pharma new headquarters opening
On the 18th of November, 2019 ENYO Pharma and Edelris inaugurated their new main offices in the Laënnec Bioparc located in Lyon. It was a great moment and we had the honor to host Mr. David Kimelfeld (Metropolis President) and Mr. Michel Le Faou (Municipal Councilor representing the mayor of the 8th arrondissement) for our “biotechnologies and territory development” round table. This new headquarter localization will open promising horizons for collaborations and contribute to ENYO’s growth.
AASLD
8-12 Novembre 2019
Boston, Massachusetts
ENYO Pharma a participé à l’AASLD meeting à Boston, a présenté quatre posters et fait une présentation orale autour des agonistes FXR utilisés pour traiter la NASH et HBV.
Pendant la conférence, ENYO Pharma a également organisé un symposium pour discuter des avancées récentes en matière de compréhension de la réplication du virus de l’hépatite B (VHB) et de la capacité potentielle des agonistes du récepteur farnésoïde X (FXR),
Targeting Immunometabolism in Autoimmune Diseases and Inflammation conference
22 octobre 2019
New York, USA
ENYO Pharma participera au “Targeting Immunometabolism in Autoimmune diseases and Inflamamtion conference” à New York et présentera le poster “A novel small molecule modulating mitochondrial activity improves inflammation in a diet-induced NASH model”
Dernière press release 